Down regulation of beta-receptors by bupropion and its major metabolite in mouse brain.
Mice were treated with bupropion Compound II (major metabolite of bupropion) or desmethylimpramine (DMI) twice a day intraperitoneally for either 1 or 3 weeks. The binding of dihydroalprenolol and spiroperidol in the frontal cortex and limbic forebrain areas were analyzed. There was a significant reduction in beta-receptors in the frontal cortex induced by DMI at both times examined. Bupropion showed a significant reduction of beta-receptor in the frontal cortex by 3 weeks. Though propiophenone did not have any significant effect on beta-receptors in the frontal cortex, it down-regulated beta-receptors in the limbic forebrain area significantly by 1 and 3 weeks. There was no significant effect of buropion or propiophenone on the binding of spiroperidol either in the cortex (S2 receptor) or in the limbic forebrain (dopaminergic). These results show that bupropion may exert part of its clinical effect through its metabolite propiophenone.
D000818:Animals; D001923:Brain Chemistry / Q000187:drug effects*; D016642:Bupropion; D004082:Dihydroalprenolol; D066298:In Vitro Techniques; D007700:Kinetics; D008297:Male; D051379:Mice; D011427:Propiophenones / Q000378:metabolism / Q000494:pharmacology*; D011943:Receptors, Adrenergic, beta / Q000187:drug effects*; D013134:Spiperone
D011427:Propiophenones; D011943:Receptors, Adrenergic, beta; D016642:Bupropion; D013134:Spiperone; D004082:Dihydroalprenolol